Dashboard
Manage Tickers

IKT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-inhibikase-therapeutics-lowers-price-target-to-23
HC Wainwright & Co. Maintains Buy on Inhib...
05/21/2024 10:45:02

HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price ...

inhibikase-therapeutics-prices-40m-registered-direct-offering-and-warrant-inducement-of-1672452-shares-of-common-stock-and-1672452-unregisted-class-b-warrants-at-combined-purchase-price-of-168-per-common-stock-and-series-a-and-b-warrant
Inhibikase Therapeutics Prices $4.0M Regis...
05/20/2024 12:07:10

inhibikase-therapeutics-q1-2024-gaap-eps-073-beats-079-estimate-cash-97m
Inhibikase Therapeutics Q1 2024 GAAP EPS $...
05/16/2024 07:06:46

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate o...

inhibikase-therapeutics-announces-request-for-withdrawal-of-s-1-registration-statement-no-securities-have-been-sold-in-connection-with-the-offering-described-in-the-registration-statement
Inhibikase Therapeutics Announces Request ...
05/15/2024 13:13:34

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company...

inhibikase-therapeutics-announces-final-pre-ind-meeting-outcomes-for-ikt-001pro-for-pulmonary-arterial-hypertension
Inhibikase Therapeutics Announces Final Pr...
05/09/2024 12:52:14

- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary A...

why-vaxxinity-shares-are-trading-lower-by-around-55-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Vaxxinity Shares Are Trading Lower By ...
04/22/2024 17:26:48

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
04/22/2024 16:31:48

inhibikase-therapeutics-issues-letter-to-shareholders-and-provides-update-on-development-programs-says-201-trial-is-75-enrolled
Inhibikase Therapeutics Issues Letter To S...
04/18/2024 20:37:32

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein ...

inhibikase-therapeutics-announces-apr-5-pre-ind-meeting-with-fda-for-ikt-001pro-in-pulmonary-arterial-hypertension
Inhibikase Therapeutics Announces Apr. 5 P...
04/03/2024 12:07:57

inhibikase-therapeutics-q4-eps-064-beats-085-estimate-sales-100k-down-from-6357k-yoy
Inhibikase Therapeutics Q4 EPS $(0.64) Bea...
03/28/2024 03:45:50

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate o...

inhibikase-therapeutics-fy23-eps-357-cash-position-133m-as-of-dec-31
Inhibikase Therapeutics FY23 EPS $(3.57); ...
03/27/2024 20:38:40

hc-wainwright--co-reiterates-buy-on-inhibikase-therapeutics-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on Inhi...
03/07/2024 16:26:19

HC Wainwright & Co. analyst Edward White reiterates Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $27 pr...

inhibikase-therapeutics-to-provide-trial-update-for-risvodetinib-at-the-2024-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurological-disorders
Inhibikase Therapeutics To Provide Trial U...
03/07/2024 13:37:27

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company...

hc-wainwright--co-maintains-buy-rating-for-inhibikase-therapeutics-heres-what-you-need-to-know
HC Wainwright & Co. Maintains Buy Rating f...
03/05/2024 17:00:30

hc-wainwright--co-maintains-buy-on-inhibikase-therapeutics-maintains-27-price-target
HC Wainwright & Co. Maintains Buy on Inhib...
03/05/2024 15:50:51

HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $27 pri...

inhibikase-therapeutics-announces-full-outcomes-of-its-pre-nda-meeting-with-the-fda-for-ikt-001pro
Inhibikase Therapeutics Announces Full Out...
02/28/2024 21:51:57

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company...

inhibikase-reports-preliminary-outcomes-of-pre-nda-meeting-with-fda-on-pathway-for-approval-for-ikt-001pro-in-blood-and-gastrointestinal-cancers-says-given-specific-guidance-on-manufacturing-requirements-necessary-to-complete-nda
Inhibikase Reports Preliminary Outcomes Of...
02/07/2024 12:57:50

inhibikase-therapeutics-announces-publication-highlighting-results-from-its-phase-1-studies-with-risvodetinib
Inhibikase Therapeutics Announces Publicat...
01/29/2024 14:06:34

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
01/26/2024 17:31:09

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
01/25/2024 17:31:07

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION